Communiqués Alnylam Pharmaceuticals, Inc.

Actions

ALNY

US02043Q1076

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
219,72 ^USD	-4,96%		-14,16%	-44,75%

17/09	Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
14/09	Transcript : Alnylam Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 10:00 AM

Communiqués

29/09	AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM	BU
02/09	Alnylam to Webcast Presentations at Upcoming September Investor Conferences	BU
31/08	Alnylam présente de nouvelles données lors du congrès de l’ESC 2026, qui confirment l’efficacité de l’inhibition de la TTR par ARNi chez les populations de patients atteints d’ATTR-CM et dans différents contextes thérapeutiques	BU
30/08	Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings	BU
24/08	Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026	BU
30/07	Alnylam: Q2 Earnings Snapshot	AQ
30/07	Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress	BU
16/07	Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results	BU
15/07	Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease	BU
12/06	Alnylam to Host Tenth “RNAi Roundtable” Webcast Series	BU
03/06	Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics	BU
19/05	Alnylam Issues 2025 Corporate Responsibility Report	BU
19/05	Alnylam Pharmaceuticals : 2025 REPORT	PU
13/05	De nouvelles analyses de données présentées lors du congrès Heart Failure 2026 démontrent les bénéfices cliniques solides et constants du vutrisiran en tant qu’option thérapeutique de première intention chez toutes les populations	BU
12/05	New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden	BU
07/05	Alnylam to Webcast Presentations at Upcoming Investor Conferences	BU
05/05	Alnylam présentera de nouvelles analyses lors du congrès Heart Failure 2026, soulignant le profil clinique constant du vutrisiran dans l’ATTR-CM	BU
04/05	Alnylam Pharmaceuticals : Q1 2026 Presentation ›	PU
04/05	Alnylam Pharmaceuticals : Q1 2026 GAAP/Non-GAAP Reconciliation ›	PU
04/05	Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM	BU
30/04	Alnylam: Q1 Earnings Snapshot	AQ
30/04	Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress	BU
16/04	Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results	BU
30/03	New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management	BU
24/03	Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association	BU